Rejoovenate Bio is a fertility biotech company focused on addressing age-related declines in egg quality. As women age, biological changes reduce the likelihood of successful fertilization and healthy pregnancy. Rejoovenate is developing laboratory-based solutions designed to improve reproductive outcomes by targeting the underlying biology of reproductive aging—without systemic exposure. Our approach is built to integrate seamlessly into existing IVF workflows, enabling fertility clinics to offer more effective options for patients of advanced maternal age. By focusing on egg quality rather than increasing treatment intensity, we aim to expand reproductive choice while improving efficiency and success rates in assisted reproduction. Looking ahead, Rejoovenate is building a broader platform in reproductive longevity, with the long-term goal of extending female healthspan beyond fertility.

Rejoovenate Bio is a fertility biotech company focused on addressing age-related declines in egg quality. As women age, biological changes reduce the likelihood of successful fertilization and healthy pregnancy. Rejoovenate is developing laboratory-based solutions designed to improve reproductive outcomes by targeting the underlying biology of reproductive aging—without systemic exposure. Our approach is built to integrate seamlessly into existing IVF workflows, enabling fertility clinics to offer more effective options for patients of advanced maternal age. By focusing on egg quality rather than increasing treatment intensity, we aim to expand reproductive choice while improving efficiency and success rates in assisted reproduction. Looking ahead, Rejoovenate is building a broader platform in reproductive longevity, with the long-term goal of extending female healthspan beyond fertility.